SCHEMBL6676808

SCHEMBL6676808

COc1cccc(C(=O)Nc2ccc(/C=C/c3ccccc3)cc2C(=O)O)c1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
SNCA P37840 2/20 0.60
POLB P06746 2/20 0.60
RAB9A P51151 5/20 0.56
NPC1 O15118 4/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
PYGM P11217 1/20 0.56
KDM4E B2RXH2 1/20 0.55
GFER P55789 1/20 0.55
MAPT P10636 1/20 0.55
KCNK3 O14649 1/20 0.54
KCNK9 Q9NPC2 1/20 0.54
MAOB P27338 1/20 0.54
HTT P42858 1/20 0.53
AKR1C2 P52895 1/20 0.53
AKR1C1 Q04828 1/20 0.53
CA2 P00918 1/20 0.53
ALDH1A1 P00352 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6676810 1.00 MEN1 (0.61) MEN1KMT2ASNCAPOLBRAB9A
SCHEMBL7643672 0.92 MEN1 (0.60) MEN1KMT2ASNCAPOLBRAB9A
SCHEMBL7643669 0.92 MEN1 (0.60) MEN1KMT2ASNCAPOLBRAB9A
SCHEMBL6677951 0.91 KDM4E (0.58) MEN1KMT2ASNCARAB9ANPC1
SCHEMBL6677957 0.91 KDM4E (0.58) MEN1KMT2ASNCARAB9ANPC1
SCHEMBL6673496 0.85 MEN1 (0.62) MEN1KMT2ASNCAGFERMAPT
SCHEMBL6674346 0.85 MEN1 (0.62) MEN1KMT2ASNCAGFERMAPT
SCHEMBL2271821 0.85 SNCA (0.61) MEN1KMT2ASNCAPOLBRAB9A
SCHEMBL2271828 0.85 SNCA (0.61) MEN1KMT2ASNCAPOLBRAB9A
SCHEMBL6677116 0.84 CHEK1 (0.70) MEN1KMT2APOLBRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1289936-B1 SUBSTITUTED STILBENES AS GLUCOSE UPTAKE ENHANCERS TELIK INC (US) 2004-10-20 EP claimed
US-6479548-B2 P-(BENZOYLAMINO)STILBENE DERIVATIVES TELIK, INC. 2002-11-12 US claimed
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers TELIK, INC. 2002-03-14 US claimed
EP-1289936-B1 SUBSTITUTED STILBENES AS GLUCOSE UPTAKE ENHANCERS TELIK INC (US) 2004-10-20 EP disclosed
US-6479548-B2 P-(BENZOYLAMINO)STILBENE DERIVATIVES TELIK, INC. 2002-11-12 US disclosed
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers TELIK, INC. 2002-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032218-A1 Substituted stilbenes as glucose uptake enhancers SLC2A1, SLC2A8, SLC2A2 MEN1 2354/4885KMT2A 3788/4885SNCA 3814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.